Hashimoto’s Disease Plasma

About Hashimoto’s Disease Plasma

Hashimoto’s Disease Plasma for Autoimmune Thyroid Research

Hashimoto’s Disease Plasma is collected from IRB-consented donors clinically diagnosed with Hashimoto’s thyroiditis and processed within one day of collection to preserve labile analytes such as cytokines, proteins, and metabolites. Anticoagulant type and aliquot volume are configured per project and reported per lot. This plasma supports research into autoimmune thyroid destruction, the systemic consequences of thyroid hormone deficiency, and biomarker discovery across the natural history of the disease. Bulk plasma is available.

Why Plasma for Hashimoto’s Thyroiditis Research

Hashimoto’s disease is a genuine autoimmune disorder: the immune system mounts a sustained response against thyroid tissue, producing lymphocytic infiltration of the gland and progressive loss of functioning thyrocytes. It is the most common cause of hypothyroidism in iodine-sufficient populations. Circulating specimens are the practical window onto this process, because the thyroid itself is rarely biopsied in research settings.

• Autoantibodies against thyroid peroxidase and thyroglobulin are the defining serological markers of Hashimoto’s disease, and their presence and titre are how donors are stratified into biologically meaningful groups.
• Thyroid autoimmunity progresses through recognisable stages — autoantibody-positive euthyroidism, subclinical hypothyroidism with a raised TSH and preserved free T4, and overt hypothyroidism — so plasma from donors at different stages supports research into what drives progression.
• Plasma is collected without a clotting step, which preserves coagulation-sensitive analytes and makes it the preferred matrix for many cytokine, proteomic, and metabolomic platforms; classical thyroid autoantibody and thyroid function serology is conventionally run on serum, and both matrices can be supplied from the same donor.
• Thyroid hormone deficiency has broad metabolic consequences, including effects on lipid handling, which makes plasma from untreated and treated donors useful for metabolic and cardiovascular biomarker work.
• Hashimoto’s disease clusters with other autoimmune conditions such as celiac disease, type 1 diabetes, vitiligo, and pernicious anaemia, so these cohorts support research into shared autoimmune mechanisms and polyautoimmunity.
• Levothyroxine replacement normalises hormone levels without removing the underlying autoimmunity, allowing the immunological and the endocrine components of the disease to be separated in a treated cohort.

Donor Stratification Available

• Thyroid autoantibody status and titre: anti-thyroid peroxidase and anti-thyroglobulin, where documented
• Biochemical stage: euthyroid with positive autoantibodies, subclinical hypothyroidism, or overt hypothyroidism
• Treatment status: levothyroxine-treated and biochemically controlled, treated and uncontrolled, or untreated
• Goitrous or atrophic presentation where recorded
• Concurrent autoimmune conditions and family history of autoimmune disease
• Disease duration, age band, and sex assigned at birth
• Matched healthy controls available, including autoantibody-negative donors

Product Features

• Research Use Only (RUO)
• Plasma collected from clinically confirmed Hashimoto’s disease donors
• Processed within one day of collection
• IRB-approved protocols and informed consent
• Anticoagulant type specified at order where inventory permits
• Custom aliquot volumes available upon request
• Volumes and lot-specific processing details reported per lot

De-identified Donor Data

• Verified Hashimoto’s disease diagnosis
• Demographic data: age, sex assigned at birth, race/ethnicity
• Donor-reported medications, allergies, and comorbidities
• Thyroid function and autoantibody results where available
• Additional Hashimoto’s disease-specific metadata available on request

Applications

• Thyroid autoantibody assay development, calibration, and specificity testing
• Biomarker discovery for progression from subclinical to overt hypothyroidism
• Cytokine and inflammatory mediator profiling in autoimmune thyroid disease
• Proteomic and metabolomic characterisation of the hypothyroid state
• Lipid and cardiometabolic biomarker research in treated and untreated donors
• Polyautoimmunity research alongside other autoimmune cohorts
• Treatment-response and levothyroxine adequacy studies
• Control and comparator material for non-autoimmune hypothyroidism studies

Other Hashimoto’s Disease Specimen Types

• Hashimoto’s Disease Serum
• Hashimoto’s Disease Whole Blood
• Hashimoto’s Disease PBMC
• Hashimoto’s Disease Leukopak
• Hashimoto’s Disease Bulk Plasma

Compliance and Quality Assurance

• IRB-approved and HIPAA-compliant protocols
• Electronic informed consent with 21 CFR Part 11 – compliant e-signatures
• Documentation support available for regulatory review

Ordering & Customization

Hashimoto’s disease plasma is available in standard and custom volumes. For pricing, availability, international orders, or documentation requirements, please email learnmore@sanguinebio.com to ensure compatibility with your country’s regulations. To browse other disease states and collection formats, visit our human plasma page.